A blood protein linked to survival in high risk glioblastoma
Original title: Circulating Placental Growth Factor as a Prognostic Biomarker in High-Risk Glioblastoma Patients.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Researchers watched people and measured their blood, but no treatment was tested.
The short version
A protein in the blood may give a hint about how a glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary will behave, but it is not a treatment.
What was studied. Researchers followed 54 people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. They measured a blood protein called placental growth factor, or PlGF, at diagnosis and again when the tumor came back.
What they found. Among 33 people in the high risk group, those with lower PlGF at the start lived longer. Their survival was 17.6 months, compared with 8.5 months for the others. In the whole group of 54 people, the link was weaker and was not clear.
What this means, and what it doesn't
What it could mean: This is a marker, not a medicine. If larger studies agree, a blood test like this might one day help doctors see who is likely to face a harder course. That kind of information can help with planning care and with choosing trials.
What it doesn't mean: This does not mean there is a new treatment. PlGF was only measured, not changed, so nothing here was tested as therapy. This was a small study that watched people over time, and the researchers say it needs to be checked in larger groups first. It is far from everyday care, and it is not a cure.
Source: PubMed, July 20, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.